Shares of Natco Pharma gained over 3% in a weak market today after the company received a favourable judgement from Delhi High Court in a patent infringement case of Chlorantraniliprole (CTPR) process. Natco Pharma stock rose 3.51% to Rs 599.05 today against the previous close of Rs 578.75 on BSE.
Natco Pharma hits record highs on drug approvals
May 24, 2021
The shares of Natco Pharma hit record highs on Monday.
At 12:20 pm, Natco Pharma was trading at ₹1,088.00 on the BSE, up ₹97.20 or 9.81 per cent. It opened at a 52-week high of ₹1,188.95 as against the previous close of ₹990.80.
On the NSE, it was trading at ₹1,088.95, up ₹98.90 or 9.99 per cent. It hit a 52-week high of ₹1,188.05.
The company has been in focus after being among the five new companies roped in by the Centre last week to produce Amphotericin B that is used to treat Mucormycosis (black fungus) to combat the shortages being reported in parts of the country.